What Delix Therapeutics does

Delix Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Concord, Massachusetts, that is developing a novel class of therapeutics called neuroplastogens — compounds designed to promote neuroplasticity and rewire precise neural circuits without producing the hallucinogenic or dissociative effects associated with classical psychedelics. The company's core technology is the Neuroplastogen Engine, a discovery platform that has produced a proprietary library of more than 1,500 compounds built on more than 10 unique chemical scaffolds, targeting neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and substance use disorders, as well as neurodegenerative indications and cochlear synaptopathy (hidden hearing loss). Its lead clinical asset, DLX-001 (zalsupindole), has progressed through Phase 1 trials in major depressive disorder; in October 2025 the FDA cleared a Phase II trial design allowing at-home administration, a first for this therapeutic class.

The company is pre-revenue and currently monetizes only through non-dilutive grants (U.S. Department of Defense, NIH/NIDA) and equity capital. Delix has raised approximately $143 million+ cumulatively across a 2020 seed, a 2021 $70M Series A led by Artis Ventures, RA Capital Management, and OMX Ventures, a 2022 $30M convertible note and $10M Comerica credit facility, and a 2025 $25M round led by UC Davis Health Ventures. Its go-to-market model is traditional pharmaceutical commercialization — distributing through pharmacies, hospitals, and healthcare providers following FDA approval — with co-development and technology partnerships (Cellectricon, Expressive Neuroscience, Cumulus Neuroscience) supporting discovery and clinical operations. The customer base is split between two end-patient segments (treatment-resistant psychiatric patients and hearing-loss patients) and a smaller research/grant segment (U.S. DoD, NIH).

Name

Delix Therapeutics

Legal name

Delix Therapeutics, Inc.

Website

https://delixtherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Delix Therapeutics is a clinical-stage biotech developing non-hallucinogenic neuroplastogens — a proprietary class of neuroplasticity-promoting compounds — to treat neuropsychiatric conditions such as major depressive disorder, PTSD, anxiety, and hearing loss, with lead candidate DLX-001 (zalsupindole) in FDA-cleared Phase II development.

Ownership category

akta.pro rank

Product category

Neuropsychiatric Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Neuroplastogen drug discovery
• Neuropsychiatric therapeutics development
• Non-hallucinogenic psychoplastogens
• Central nervous system drug pipeline
• Neuroplasticity-promoting compounds

Headquarters

HQ city

Concord

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Development: Delix is a clinical-stage biotech company developing neuroplastogen therapeutics. The company is pre-revenue, focused on advancing compounds through clinical trials toward FDA approval for commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Delix Therapeutics is a clinical-stage biopharmaceutical company developing non-hallucinogenic neuroplastogens — a proprietary class of small molecules that promote neuroplasticity and rewire precise neural circuits to treat neuropsychiatric and neurodegenerative conditions. Its lead candidate DLX-001 (zalsupindole) is being advanced through Phase II clinical trials for major depressive disorder, with additional pipeline assets targeting PTSD, anxiety, substance use disorders, and hearing loss.

Product overview

Delix Therapeutics is developing a portfolio of neuroplastogens — novel compounds that promote neuroplasticity and deliver therapeutic benefits without hallucinogenic effects. The company's Neuroplastogen Engine discovery platform has generated more than 1500 compounds based on more than 10 unique chemical scaffolds. Lead candidate DLX-001 (zalsupindole) is in Phase II development for Major Depressive Disorder, with at-home administration approved by FDA. Additional candidates include DLX-7. The pipeline targets neuropsychiatric conditions including depression, PTSD, anxiety, substance use disorders, and hearing loss.

Differentiator

Problem solved

Functional benefit

Products and services

• DLX-001 (Zalsupindole) A non-hallucinogenic neuroplastogen lead drug candidate in clinical development for major depressive disorder. Demonstrated rapid and sustained symptom improvement (12-point reduction lasting four weeks post-treatment) without hallucinatory, dissociative, or psychotomimetic effects, with FDA clearance for at-home oral administration in the Phase II program.
• DLX-7 A lead neuroplastogen drug candidate from Delix's pipeline undergoing safety and toxicology studies as part of the company's portfolio of non-hallucinogenic psychoplastogen analogs.

Quantifiable outcome

• 12-point symptom reduction lasting four weeks post-treatment
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• CellectriconminorStrategic or Co-development PartnerPartnership announced February 2023 to accelerate drug discovery and translatability through collaboration on discovery platforms.
• Expressive NeuroscienceminorStrategic or Co-development PartnerPartnership announced February 2023 to accelerate drug discovery and translatability through neuroscience research collaboration.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Compass Pathways: Clinical-stage psychedelic-derived therapeutics company developing psilocybin therapy for treatment-resistant depression. Direct peer as both target overlapping neuropsychiatric indications through neuroplastogen-like mechanisms, but Delix's key differentiator is its non-hallucinogenic profile versus Compass's hallucinogenic approach.
• MindMed: Clinical-stage neuroscience company developing psychedelic-inspired therapies (LSD, MDMA analogs) for anxiety, ADHD, and substance use disorders. Direct peer targeting the same neuropsychiatric conditions through neuroplastogen mechanisms, though primarily with hallucinogenic compounds requiring in-clinic administration.
• GH Research: Clinical-stage biotech developing mebufotenin and other psychedelic-based therapies for treatment-resistant depression. Direct peer in the psychedelic-neuroplastogen space competing for similar patient populations and physician adoption.
• Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analogs for MDD and other psychiatric indications. Direct peer pursuing next-generation psychedelic-derived neuroplastogens with improved pharmacokinetic profiles.
• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health conditions, holding multiple platform investments including Compass Pathways. Direct peer addressing the same neuropsychiatric treatment-resistant populations through neuroplastogen mechanisms.
• Sage Therapeutics: Commercial-stage CNS biopharma company that developed Zurzuvae (zuranolone) for postpartum depression and prior MDD programs. Direct peer demonstrating both the regulatory pathway and commercial challenges in CNS depression therapeutics, with comparable neuroplasticity mechanism of action.

Emerging players

• Neumora Therapeutics: Clinical-stage neuroscience company developing precision medicines for brain diseases including depression and other neuropsychiatric conditions. Comparable emerging peer pursuing novel CNS mechanisms with similar capital-intensive development profile.
• MapLight Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS conditions including schizophrenia and Alzheimer's disease psychosis. Comparable emerging peer with similar funding profile targeting neuropsychiatric indications through novel mechanisms.
• Praxis Precision Medicines: Clinical-stage CNS-focused company developing therapies for neurological and psychiatric disorders including depression and epilepsy. Comparable emerging peer with similar stage, indication overlap, and platform-based approach to CNS drug development.

Broad incumbents

• Karuna Therapeutics: Now part of Bristol Myers Squibb following 2024 acquisition, developed xanomeline-trospium (Cobenfy) for schizophrenia. Comparable CNS therapeutics developer demonstrating successful exit pathway for novel-mechanism neuropsychiatric drugs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/delix-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds9 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delix Therapeutics